Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  therapeutic autologous dendritic cells
Find trials that include:  Any drugs shown
Results 1-8 of 8 for your search:
Start Over
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
Phase: Phase III
Type: Treatment
Age: 18 to 65
Trial IDs: 020221, NCI-2010-00822, NCT00045968
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CL-CA-P01, NCI-2015-00099, 2014-000544-15, 2015-001984-38, CL-CA-P01-00-US, NCT01875653
Vaccine Therapy and/or Glycosylated Recombinant Human Interleukin-7 after Standard Therapy in Treating Younger Patients with High Risk Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 19 months to 35 years
Trial IDs: 07-C-0206, NCI-2013-01440, 070206, 339168, NCT00526240, P6941, NCT00923351
Vaccine Therapy, Trastuzumab, and Vinorelbine Tartrate in Treating Patients With Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LCCC 0418, NCI-2013-00498, UNC-LCCC-0418, NCT00266110
Vaccine therapy in Treating Patients with Newly Diagnosed Glioblastoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: Pro00054740, NCI-2015-00856, NCT02366728
Basiliximab in Treating Patients with Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia
Phase: Phase I
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: Pro00000581, NCI-2011-03848, CDR0000579683, SPORE Project 3, DUMC-PRO00000581, NCT00626483
Vaccine Therapy in Treating Patients with Newly Diagnosed Glioblastoma Multiforme Recovering from Therapeutic Temozolomide-Induced Lymphopenia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Pro00003877, NCI-2011-03843, CDR0000589624, DUMC-8108-07-1R1, DUMC-PRO00003877, NCI-09-C-0038, NCT00639639
Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma
Phase: Phase I
Type: Treatment
Age: Over 18
Trial IDs: 201103308, NCI-2011-00484, 07-0652, NCT00683670
Start Over